A phase Ib, open-label, multi-center, single arm, dose finding study to assess safety and pharmacokinetics of the oral combination of Panobinostat and Ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia veramyelofibrosis (PP-MF) or post-essential thrombocythemiamyelofibrosis (PET-MF) (#446)